Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2023-09-05 Director's Dealing
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
3
Director's Dealing
2023-09-05 English
4
Director's Dealing
2023-09-05 English
3
Director's Dealing
2023-09-05 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports disclosing material events. The content focuses on the appointment of a new Chief Financial Officer and related officer transition details. It includes information about the new CFO's background, compensation, and severance terms. There is no financial data or comprehensive report content such as earnings, annual or quarterly financial statements, or audit results. The primary subject is a management change announcement. According to the filing definitions, announcements of changes in senior management fall under Board/Management Information (MANG). The document length is 7316 characters, which is sufficient for a detailed announcement but does not constitute a full financial report. Therefore, the correct classification is MANG with high confidence.
2023-09-05 English
Regulatory Filings 2023
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify this document as any specific filing type. According to the fallback rule, documents that do not fit any specific category should be classified as Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable. Therefore, the best classification is RNS with moderate confidence due to lack of information.
2023-08-28 English
10-Q
Interim / Quarterly Report Q2 2023
2023-08-11 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.